Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.

Abstract

With the growing complexity of treatment options for chronic lymphocytic leukemia (CLL) and variables that influence the underlying biology of this disease, providing allogeneic stem cell transplant (alloSCT) to appropriate candidates poses a challenge for transplant physicians. Novel small molecule inhibitors hold unprecedented promise for poor-risk subgroups, which will likely alter decision-making and referral patterns for transplant. In this review, we analyze what is known and may still remain true about indications for transplant based on outcomes reported in the literature recently and over the last decade.

• Authors: Racquel D Innis-Shelton, Randall S Davis, Lawrence Lamb, Shin Mineishi
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 56 Issue 6 Pg. 1626-35 (Jun 2015) ISSN: 1029-2403 [Electronic] United States
• PMID: 25308292 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Topics

• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis, genetics, therapy)
• Prognosis
• Stem Cell Transplantation
• Transplantation, Homologous